Abstract
Aortic stenosis affects a significant number of patients worldwide, and carries a dismal prognosis once symptoms develop. Unfortunately, a large number of patients present a prohibitive risk for surgical aortic valve replacement. Therefore, transcatheter aortic valve implantation has emerged as a promising technology for providing treatment to this group of patients. Currently available valves include the balloon-expandable Edwards SAPIEN valve (Edwards Lifesciences, Irvine, CA), which is usually implanted via a transfemoral or transapical approach, and the self-expanding CoreValve ReValving system (Medtronic, Minneapolis, MN), which uses only the transfemoral route. Early experience with the procedure performed on a compassionate-use basis was encouraging, and led to a number of first-in-man and feasibility studies. These trials demonstrated the safety and efficacy of valve implantation and led to CE (European Conformity) mark approval of both valves in Europe. Use of the SAPIEN valve in the United States is limited to the recently completed PARTNER (Placement of Aortic Transcatheter Valve) randomized trial comparing transcatheter and surgical aortic valve replacement in high-risk patients, and its post-trial registry. The CoreValve is not yet available in the United States. With improved device technology, better understanding of patient selection and pre- and periprocedural imaging, and greater procedural experience, widespread diffusion of transcatheter aortic valve implantation is expected.
Similar content being viewed by others
Abbreviations
- I-REVIVE:
-
Initial Registry of Endovascular Implantation of Valves in Europe
- PARTNER:
-
Placement of Aortic Transcatheter Valve
- RECAST:
-
Registry of Endovascular Critical Aortic Stenosis Treatment
- REVIVAL-II:
-
Transcatheter Endovascular Implantation of Valves II
- REVIVE II:
-
Registry of Endovascular Implantation of Valves in Europe II
- SOURCE:
-
A European Registry of Transcatheter Aortic Valve Implantation Using the Edwards Sapien Valve
- TRAVERCE:
-
Trans-Apical Surgical Delivery of the Cribier-Edwards Aortic Bioprosthesis Clinical Feasibility.
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Nkomo VT, Gardin JM, Skelton TN, et al.: Burden of valvular heart diseases: a population-based study. Lancet 2006, 368:1005–1011.
Carabello BA: Clinical practice. Aortic stenosis. N Engl J Med 2002, 346:677–682.
Iung B, Cachier A, Baron G, et al.: Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J 2005, 26:2714–2720.
Bouma BJ, van Den Brink RB, van Der Meulen JH, et al.: To operate or not on elderly patients with aortic stenosis: the decision and its consequences. Heart 1999, 82:143–148.
Otto CM, Mickel MC, Kennedy JW, et al.: Three-year outcome after balloon aortic valvuloplasty. Insights into prognosis of valvular aortic stenosis. Circulation 1994, 89:642–650.
Osswald BR, Gegouskov V, Badowski-Zyla D, et al.: Overestimation of aortic valve replacement risk by EuroSCORE: implications for percutaneous valve replacement. Eur Heart J 2009, 30:74–80.
Iung B, Himbert D, Vahanian A: A step forward in the evaluation of transcatheter aortic valve implantation. J Am Coll Cardiol 2010, 55:1091–1092.
Tuzcu EM, Kapadia SR, Schoenhagen P: Multimodality quantitative imaging of aortic root for transcatheter aortic valve implantation: more complex than it appears. J Am Coll Cardiol 2010, 55:195–197.
John D, Buellesfeld L, Yuecel S, et al.: Correlation of device landing zone calcification and acute procedural success in patients undergoing transcatheter aortic valve implantations with the self-expanding CoreValve prosthesis. JACC Cardiovasc Interv 2010, 3:233–243.
Akhtar M, Tuzcu EM, Kapadia SR, et al.: Aortic root morphology in patients undergoing percutaneous aortic valve replacement: evidence of aortic root remodeling. J Thorac Cardiovasc Surg 2009, 137:950–956.
Messika-Zeitoun D, Serfaty JM, Brochet E, et al.: Multimodal assessment of the aortic annulus diameter: implications for transcatheter aortic valve implantation. J Am Coll Cardiol 2010, 55:186–194.
Nietlispach F, Leipsic J, Al-Bugami S, et al.: CT of the ilio-femoral arteries using direct aortic contrast injection: proof of feasibility in patients screened towards percutaneous aortic valve replacement. Swiss Med Wkly 2009, 139:458–462.
Zajarias A, Cribier AG: Outcomes and safety of percutaneous aortic valve replacement. J Am Coll Cardiol 2009, 53:1829–1836.
Cribier A, Eltchaninoff H, Bash A, et al.: Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002, 106:3006–3008.
Cribier A, Eltchaninoff H, Tron C, et al.: Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol 2004, 43:698–703.
Webb JG, Chandavimol M, Thompson CR, et al.: Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 2006, 113:842–850.
Lichtenstein SV, Cheung A, Ye J, et al.: Transapical transcatheter aortic valve implantation in humans: initial clinical experience. Circulation 2006, 114:591–596.
Grube E, Schuler G, Buellesfeld L, et al.: Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol 2007, 50:69–76.
Fraccaro C, Napodano M, Tarantini G, et al.: Expanding the eligibility for transcatheter aortic valve implantation the trans-subclavian retrograde approach using: the III generation CoreValve revalving system. JACC Cardiovasc Interv 2009, 2:828–833.
Ruge H, Lange R, Bleiziffer S, et al.: First successful aortic valve implantation with the CoreValve ReValving System via right subclavian artery access: a case report. Heart Surg Forum 2008, 11:E323–E324.
Schaechinger V: Results from The PARTNER EU Trial: Primary Endpoint Analysis. Presented at the EuroPCR. Barcelona, Spain; May 19–22, 2009.
• Piazza N, Grube E, Gerckens U, et al.: Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. EuroIntervention 2008, 4:242–249. This paper discusses the results of a large, contemporary series of patients undergoing TAVI using the CoreValve ReValving system.
Cribier A, Eltchaninoff H, Tron C, et al.: Treatment of calcific aortic stenosis with the percutaneous heart valve: mid-term follow-up from the initial feasibility studies: the French experience. J Am Coll Cardiol 2006, 47:1214–1223.
• Rodes-Cabau J, Webb JG, Cheung A, et al.: Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol 2010, 55:1080–1090. This paper discusses the recently published Canadian experience of TF and TA TAVI.
• Masson JB, Kovac J, Schuler G, et al.: Transcatheter aortic valve implantation: review of the nature, management, and avoidance of procedural complications. JACC Cardiovasc Interv 2009, 2:811–820. This is a comprehensive review of complications encountered with TAVI.
Kapadia SR, Svensson L, Tuzcu EM: Successful percutaneous management of left main trunk occlusion during percutaneous aortic valve replacement. Catheter Cardiovasc Interv 2009, 73:966–972.
Babaliaros V: Presented at the American College of Cardiology’s 59th Annual Scientific Session and i2 Summit. Atlanta, GA; March 14–16, 2010.
Svensson LG, Dewey T, Kapadia S, et al.: United States feasibility study of transcatheter insertion of a stented aortic valve by the left ventricular apex. Ann Thorac Surg 2008, 86:46–54; discussion 54–55.
Webb JG, Pasupati S, Humphries K, et al.: Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. Circulation 2007, 116:755–763.
theheart.org: FRANCE: Transcatheter-valve registry permits "observation" of CoreValve, Sapien differences. Available at http://www.theheart.org/article/1021541.do. Accessed December 7, 2009.
Piazza N, Onuma Y, Jesserun E, et al.: Early and persistent intraventricular conduction abnormalities and requirements for pacemaking after percutaneous replacement of the aortic valve. JACC Cardiovasc Interv 2008, 1:310–316.
Andersen HR, Knudsen LL, Hasenkam JM: Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs. Eur Heart J 1992, 13:704–708.
theheart.org: Low 30-day and six-month mortality for transfemoral valve implantation in PARTNERS EU and SOURCE. Available at http://www.theheart.org/article/910857.do. Accessed November 2, 2009.
Walther T, Simon P, Dewey T, et al.: Transapical minimally invasive aortic valve implantation: multicenter experience. Circulation 2007, 116(11 Suppl):I240–I245.
Grube E, Laborde JC, Zickmann B, et al.: First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis for interventional treatment of aortic valve stenosis. Catheter Cardiovasc Interv 2005, 66:465–469.
Grube E, Laborde JC, Gerckens U, et al.: Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation 2006, 114:1616–1624.
Tamburino C, Capodanno D, Mule M, et al.: Procedural success and 30-day clinical outcomes after percutaneous aortic valve replacement using current third-generation self-expanding CoreValve prosthesis. J Invasive Cardiol 2009, 21:93–98.
Wenaweser P, Buellesfeld L, Gerckens U, Grube E: Percutaneous aortic valve replacement for severe aortic regurgitation in degenerated bioprosthesis: the first valve in valve procedure using the Corevalve Revalving system. Catheter Cardiovasc Interv 2007, 70:760–764.
Khawaja MZ, Haworth P, Ghuran A, et al.: Transcatheter aortic valve implantation for stenosed and regurgitant aortic valve bioprostheses CoreValve for failed bioprosthetic aortic valve replacements. J Am Coll Cardiol 2010, 55:97–101.
Ruiz CE, Laborde JC, Condado JF, et al.: First percutaneous transcatheter aortic valve-in-valve implant with three year follow-up. Catheter Cardiovasc Interv 2008, 72:143–148.
Ussia GP, Mule M, Tamburino C: The valve-in-valve technique: transcatheter treatment of aortic bioprothesis malposition. Catheter Cardiovasc Interv 2009, 73:713–716.
Ng AC, van der Kley F, Delgado V, et al.: Percutaneous valve-in-valve procedure for severe paravalvular regurgitation in aortic bioprosthesis. JACC Cardiovasc Imaging 2009, 2:522–523.
Bruschi G, Demarco F, Oreglia J, et al.: Transcatheter aortic valve-in-valve implantation of a CoreValve in a degenerated aortic bioprosthesis. J Cardiovasc Med (Hagerstown) 2010, 11:182–185.
Singh IM, Tuzcu EM, Shishehbor MH, et al.: Percutaneous treatment of aortic valve stenosis. Cleve Clin J Med 2008, 75:805–812.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Krishnaswamy, A., Tuzcu, E.M. & Kapadia, S.R. Update on Transcatheter Aortic Valve Implantation. Curr Cardiol Rep 12, 393–403 (2010). https://doi.org/10.1007/s11886-010-0126-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11886-010-0126-5